A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT02236013 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Gilteritinib
DRUG: Idarubicin
DRUG: Cytarabine
DRUG: Daunorubicin

Sponsor

Astellas Pharma Global Development, Inc.